Anja Harmeier News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Anja harmeier. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Anja Harmeier Today - Breaking & Trending Today
Rewind Therapeutics has raised further funding that has seen Sunstone Life Science Ventures joining as a new investor. The funding round has seen participation of current investors Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven. ....
VC Daily: Biotechs Seek New Skill Set From Scientists Entering Field morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Rewind Therapeutics ("Rewind"), a private Belgian biotech company developing innovative first-in-class remyelinating therapies for multiple. ....
7 Pureos Bioventures has hit a $205m final close for its debut fund, which will look to back developers of novel biologica Sorry, you need to subscribe to read this article. If you would like to access this article you must become a Premium Subscriber. Premium subscribers receive complete access to our daily breaking news, premium stories, weekly Fundraising & IR Review, Knowledge Bank and LP profiles - all which are accessible via our mobile platform. ....
Pureos Bioventures Raises Additional USD35M; Fund Totals USD205M The firm had announced a USD170m close in September 2020. The supporters of the first Pureos fund include strategic partners, such as pharmaceutical and biotech companies as well as a large contract manufacturer, family offices, pension funds, fund-of-funds and other institutional investors. Led by partners Klaus Breiner, Dominik Escher, Anja Harmeier, and Martin Münchbach, the firm will exclusively invest in innovative private drug development companies with an emphasis on novel biological drugs and emerging modalities such as nucleic acid, cell- and gene therapies. The fund’s portfolio companies are built on strong teams advancing therapies across a broad spectrum of indications including oncology, immunology, ophthalmology, rare diseases and neuroscience. ....